The effects of weekly alendronate therapy in Taiwanese males with osteoporosis.
|
| Abstract |
The aim of this study was to evaluate the efficacy, safety, and tolerability of weekly alendronate administration on male osteoporosis in Taiwan. This 6-month, randomized, open-label controlled trial enrolled 46 men with osteoporosis who were randomized to either 70 mg alendronate once weekly (n = 23) or control (n = 23). Bone mineral density (BMD) of lumbar spine and hip and biochemical bone turnover markers were measured; adverse events and tolerability were assessed. Subjects treated with alendronate showed a significant increase in BMD of 5.5% (vs. 2% in control group) at the lumbar spine and 2.7% (vs. 0.7%) at the femoral neck (P < 0.05) at 6 months, respectively. There were also significant decreases in serum level of bone formation marker (bone-specific alkaline phosphatase) and urinary excretion of bone resorption marker (deoxypyridinoline) at 3 and 6 months. Thus, alendronate showed anti-osteoporotic effects by increasing BMD and decreasing the concentrations of bone markers. The adverse events were mild and showed no significant difference between the two groups on safety assessments.
|
|---|---|
| Authors | Jawl-Shan Hwang, Miaw-Jene Liou, Cheng Ho, Jen-Der Lin, Yu-Yao Huang, Chao-Jan Wang, Keh-Sung Tsai, Jung-Fu Chen |
| Journal | Journal of bone and mineral metabolism (J Bone Miner Metab) Vol. 28 Issue 3 Pg. 328-33 (May 2010) ISSN: 1435-5604 [Electronic] Japan |
| PMID | 20012918 (Publication Type: Journal Article, Randomized Controlled Trial) |
| Chemical References |
|
| Topics |
|
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!